Pulmonary Disease, Chronic Obstructive
945
22
33
757
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
316 trials with published results (33%)
Research Maturity
757 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.2%
49 terminated out of 945 trials
93.9%
+7.3% vs benchmark
29%
273 trials in Phase 3/4
42%
316 of 757 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 757 completed trials
Clinical Trials (945)
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
Family-centred Pulmonary Rehabilitation to Empower Carers
Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
Hypoxia and Heart Rate Variability
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Tiotropium/Salmeterol Inhalation Powder in COPD
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Generative AI for Medication Counselling and Adherence in Community Pharmacies
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor
Innate Immunity in Ozone-induced Airway Inflammation in COPD
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease